Ulcers - Pipeline Review, H2 2013 report provides an
overview of the indication’s therapeutic pipeline. This report provides
information on the therapeutic development for Ulcers, complete with latest
updates, and special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for Ulcers. Ulcers
- Pipeline Review, Half Year is built using data and information sourced from
report proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from company/university
sites and industry-specific third party sources, put together by publisher
team.
Scope
- A snapshot of the global therapeutic scenario for Ulcers.
- A review of the Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ulcers pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ulcers pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Spanning over 44 pages, 19 Tables and 14
Figures “Ulcers - Pipeline Review, H2
2013” report provide Ulcers Overview, Therapeutics Development, Ulcers -
Therapeutics under Development by Companies, Drug Profiles, Ulcers - Product
Development Milestones, Ulcers - Discontinued Products, Appendix and the report
cover also 4 companies - Ahn-Gook Pharmaceutical Co., Ltd., Angelini Group, Laboratorios Farmaceuticos Rovi, S.A., TechnoPhage SA.
Inquiry for more information
visit: http://www.marketresearchreports.com/global-markets-direct/ulcers-pipeline-review-h2-2013
Find All Pharma and Healthcare Reports at:
No comments:
Post a Comment
Note: only a member of this blog may post a comment.